AzTrials
AzTrials

SepsisnSePNCT03777670

nSeP: Detecting Neonatal Sepsis by Immune-Metabolic Network Analysis

An observational study of Sepsis, run by Cardiff and Vale University Health Board at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Diagnosis of neonatal sepsis remains a challenge due to non-specific signs and diagnostic inaccuracies. Studies have shown that this could lead to overdiagnosis and overuse of antibiotic treatment, with potential long-term adverse effects. Read more about this study

Who is it for?
Ages Up to 4 months
Conditions the study is for
Sepsis
What is being tested?
Blood test
How many people
1,000 participants
Where
1 siteUnited Kingdom
Study dates
26 Feb 2020to 28 Feb 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 4 months
  • All sexes
  • Child

Study population: Newborn infants in the neonatal unit with a suspicion of sepsis

Who may be able to join

  • Screened with traditional tests (full-blood count [FBC], inflammatory markers like C-reactive protein [CRP], and blood-culture) for suspected sepsis (including non-infective inflammatory conditions) and started on antibiotics - potential cases.
  • Being sampled for non-septic conditions (bloods sampling for routine monitoring, jaundice, hypoglycaemia, etc.) - controls.
  • Informed consent from parents to use blood and stool samples (initial sample and 24-hour sample) and clinical data for study.

Who cannot join

  • Language and communication issues, which will make it difficult to explain study and request informed consent.
  • When an infant has a high chance of mortality in the next 24-hours.

Trial locations and contacts

1 site in 1 country.

Peter Ghazal, PhD contact

29207 44721

ghazalp@cardiff.ac.uk

United Kingdom1 site, 1 recruiting
  • University Hospital of Wales

    Cardiff, South Glamorgan, CF14 4XN

    Mallinath Chakraborty, PhD, +44 2920 742276, chakrabortym@cardiff.ac.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: Detecting Neonatal Sepsis by Immune-Metabolic Network Analysis

Diagnosis of neonatal sepsis remains a challenge due to non-specific signs and diagnostic inaccuracies. Studies have shown that this could lead to overdiagnosis and overuse of antibiotic treatment, with potential long-term adverse effects.

A systems approach towards diagnosing neonatal sepsis has been shown to have high accuracy in initial studies. This study aims to recruit a large validation cohort to confirm findings.

Read the detailed description

Several studies have shown that changes in host gene expression may occur pre- symptomatically in response to infection in any part of the body, with the continuous interaction between blood and tissue allowing blood cells to act as biosensors for the changes (Manger and Relman, 2000, Liew et al., 2006). Genome wide analysis reveals coordinate expression that develop networks causally linked through pathways.

Earlier studies from our group investigating optimal methods for the sampling and extraction of neonatal whole transcription products (RNA) demonstrated the first feasibility studies for using genome wide RNA analysis as a methodological approach for identifying host biomarkers of infection and vaccination in early life (Smith et al., 2007, Flanagan et al., 2013). The sampling methods were further refined in 2015 with the development of a single drop methodology that has been extensively tested in a wide range of settings including the collection of neonatal samples in the home, at the point of Guthrie testing by mid-wives. Details of these methods have been recently submitted to the Nature Protocols journal. Further, we conducted early on virtual clinical trials using a super computing framework that simulated several 100,000 neonatal whole blood samples for predicting infection (Khondoker et al., 2010). Those investigations showed the requirement for multiple markers and ideally in discrete biological pathways underpinning causality (Khondoker et al., 2010, Watterson and Ghazal, 2010). Those investigations provided a strong foundation for initiating a case-control of neonatal sepsis (Dickinson et al., 2015). Accordingly, we were the first group to publish studies investigating the systemic immune response in neonates to sepsis by measuring the activity of all known human genes (Smith et al Nature comm. 2014). These computationally intensive investigations led to uncovering, for the first time, the pathway biology underlying neonatal sepsis with blood samples taken at the first clinical signs of suspecting an infection. A combination of machine learning, statistical and deep pathway biology analyses led to the identification of a 52-gene panel of biologically connected network modules. The modules comprise three central pathways, innate-immune or inflammatory, adaptive-immune and unexpectedly metabolic. The expression levels of particular combinations of biomarkers, and specifically those of a pathway previously unconnected to immune responses, gives an unusually high diagnostic quality. Despite patient heterogeneity, the 52-node dual biomarker network had greater than 99% accuracy for detecting bacterial infection with 100% sensitivity showing superior performance to previously characterised markers. Furthermore, these specific combinations of biomarkers allowed the detection of neonatal sepsis in samples which had displayed blood-culture negative results, illustrating the specific diagnostic benefits of the particular combinations of biomarkers. The unexpectedly high accuracy and sensitivity values could not have resulted from the investigation of any of the individual biomarkers alone, nor could they have been predicted. A critical part of these findings is the requirement of metabolic pathways for increasing both sensitivity and specificity. A subset of the metabolic markers encompass ligands (specifically small and medium chain fatty acids) that are derived from microbial metabolism, in particular from commensals and which are reflected in the faecal microbiome. To date these studies provide a proof of concept but need independent confirmatory studies as well as investigating specificity against non-bacterial (viral and fungal) infections and sterile inflammation. The urgent unmet medical question is whether predictive host pathways of infection can be used to first identify whether a patient is infected at or before clinical presentation and, to further discriminate between the type of infection (in particular bacterial or viral) and predictability of sepsis.

Conditions
Sepsis
Being tested
Blood test
Keywords
Newborn
Medical subject headings
Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood testDiagnostic test

    Drop of blood for RNA and metabolic analysis

Study groups in NCT03777670
Study groupRoleWhat they receive
CasesInfants with suspected sepsis
Receives: Diagnostic Test: Blood test
ControlsInfants with no suspicion of sepsis
Receives: Diagnostic Test: Blood test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sepsis

    Immune signature of sepsis

    Measured: 5-years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2018
  2. Study start26 Feb 2020
  3. Primary completion28 Feb 2023 (estimated)
  4. Study completion28 Feb 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03777670
Sponsor's protocol ID
248404
Acronym
nSeP
Status last verified
Apr 2020
First submitted
13 Dec 2018
Last updated
7 Apr 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Chakraborty M, Rodrigues PRS, Watkins WJ, Hayward A, Sharma A, Hayward R, Smit E, Jones R, Goel N, Asokkumar A, Calvert J, Odd D, Morris I, Doherty C, Elliott S, Strang A, Andrews R, Zaher S, Sharma S, Bell S, Oruganti S, Smith C, Orme J, Edkins S, Craigon M, White D, Dantoft W, Davies LC, Moet L, McLaren JE, Clarkstone S, Watson GL, Hood K, Kotecha S, Morgan BP, O'Donnell VB, Ghazal P. nSeP: immune and metabolic biomarkers for early detection of neonatal sepsis-protocol for a prospective multicohort study. BMJ Open. 2021 Dec 30;11(12):e050100. doi: 10.1136/bmjopen-2021-050100.

    PubMed 37010923

Questions about this trial

What is this clinical trial studying?

An observational study of Sepsis, run by Cardiff and Vale University Health Board at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Peter Ghazal, PhD (29207 44721, ghazalp@cardiff.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sepsis (time frame: 5-years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03777670, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in